Because tirzepatide is a peptide which is essentially a short chain of amino acidsit is much more fragile than traditional pill-form medications
11 Preliminary real-world data further suggest that biweekly interval dosing of GLP-1 therapy can maintain prior weight loss for an average of 32 weeks, with an average of 2% additional weight loss and 84% of patients remaining on biweekly interval dosing
Future availability of more affordable options will depend on drug administration decisions and patent expiration dates
Saini underlines the importance of dietitians being more involved in the nutritional management of patients using GLP-1s, saying, These [medications] are directly reducing appetite, and when we're reducing appetite, we're reducing caloric intake
Additionally, if you notice delayed wound healing, hair thinning, or easy bruising developing after starting therapy, discuss these findings with your provider, as they may indicate nutritional factors or other issues requiring attention